Vetmedin 0.75 mg/ml solution for injection for dogs

দেশ: আয়ার্লণ্ড

ভাষা: ইংরেজি

সূত্র: HPRA (Health Products Regulatory Authority)

এখন এটা কিনুন

Download DSU (DSU)
08-08-2023

সক্রিয় উপাদান:

Pimobendan

থেকে পাওয়া:

Boehringer Ingelheim Vetmedica GmbH

এটিসি কোড:

QC01CE90

INN (আন্তর্জাতিক নাম):

Pimobendan

ডোজ:

0.75 milligram(s)/millilitre

ফার্মাসিউটিকাল ফর্ম:

Solution for injection

প্রেসক্রিপশন টাইপ:

POM: Prescription Only Medicine as defined in relevant national legislation

থেরাপিউটিক এলাকা:

pimobendan

অনুমোদন অবস্থা:

Authorised

অনুমোদন তারিখ:

2014-08-22

পণ্য বৈশিষ্ট্য

                                Health Products Regulatory Authority
06 August 2019
CRN008VPD
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 0.75 mg/ml solution for injection for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Pimobendan 0.75 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
To initiate treatment of canine congestive heart failure originating
from valvular insufficiency (mitral and/or tricuspid
regurgitation) or dilated cardiomyopathy.
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in cases of hypertrophic cardiomyopathies or clinical
conditions where an augmentation of cardiac output is not
possible for functional or anatomical reasons (e.g. aortic stenosis).
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
In case of accidental subcutaneous injection temporary swelling and
mild to slight resorptive inflammatory reactions can occur
at or below the injection site.
For single administration only.
The product should be used for the initiation of treatment of
congestive heart failure in dogs, following a risk:benefit
assessment by the responsible veterinarian, taking into account the
overall health status of the dog. Before treatment,
diagnosis should be made by the means of a comprehensive physical and
cardiac examination which should include
echocardiography or radiography where appropriate.
Health Products Regulatory Authority
06 August 2019
CRN008VPD
Page 2 of 4
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the label to the physician.
Wash hands af
                                
                                সম্পূর্ণ নথি পড়ুন
                                
                            

এই পণ্য সম্পর্কিত সতর্কতা অনুসন্ধান করুন

দস্তাবেজ ইতিহাস দেখুন